Located in capital city Riyadh, the 1,000+ bed hospital is the national referral center for oncology, organ transplantations, cardiac surgery and genetic diseases. Now, with this deal, it is set to become the reference center for ADAMTS13 activity testing in the country.
With state-of-the-art laboratory equipment comparable with major reference laboratories internationally, the hospital is part of a three-hospital network encompassing the cities of Riyadh, Jeddah and Medina.
The hospital had been outsourcing all of its TTP suspected samples to Bioscentia in Germany, incurring extra costs and turnaround times of over 3 weeks. This resulted in a very high risk to patients of TTP testing before obtaining the clinical result.
This milestone deal was achieved in competition with the ELISA test from Technozym which appeared to be cheaper than our solution, but by deploying the ValueSelling methodology we were able to reveal several problems related to the inherent business issue of managing suspected TTP patients – while on the face of it, ELISA was cheaper, the minimum 24-hour time interval from test to result, in addition to the 3-hours hands-on time by technicians, and the high risk of trained technicians not being available during an emergency, turned the tide in our favor.
What clinched the deal, according to the financial decision-makers at the hospital, was the health-economic study presented by our local partner Abdullah Fouad, which highlighted the global hospital savings in terms of reduction of PLEX.
Congratulations to our EEMEAI team and local partner Abdullah Fouad for making this great success possible!



